Yoni Epstein

Leading Interventional Cardiology Devices Companies | $42.3B by 2031 | 6.4% CAGR | 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲: https://lnkd.in/ddS4A-7c Insights to Impact ❤️⚕️ The Future of Cardiac Care Is Shifting from Open Surgery to Precision Intervention Where Imaging, Intelligence, and Innovation Converge Inside the Artery. The #InterventionalCardiologyDevices Market is witnessing strong momentum as #cardiovasculardisease remains one of the leading causes of mortality worldwide. Advances in minimally invasive procedures, intravascular imaging, and next-generation coronary technologies are redefining how physicians diagnose and treat complex heart conditions. 🌎 #NorthAmerica led the global market in 2025, accounting for 33.9% of total revenue, supported by a high prevalence of #coronary_arterydisease, advanced healthcare infrastructure, favorable reimbursement frameworks, and continuous product innovation. 🔬 Drug-eluting stents (#DES) are projected to be the fastest-growing product category, expanding at a CAGR of 7.6%. Their ability to reduce restenosis rates and improve long-term patient outcomes continues to drive widespread adoption across catheterization laboratories globally. 🔹 Within imaging and diagnostic technologies, #IVUS (Intravascular Ultrasound) and #OCT (Optical Coherence Tomography) catheters are expected to record a CAGR of 6.7%, reflecting growing demand for precision-guided interventions. Meanwhile, #angiographycatheters continue to hold the largest market share due to their critical role in #cardiovascular_diagnostics and procedural planning. 🏆 Boston Scientific, Medtronic, and Abbott are among the major players in the #interventional_cardiologydevices_market. These companies offer comprehensive coronary, peripheral & structural heart portfolios, emphasizing next-generation stents, #intravascular_imaging, and physiology-guided intervention. 🔹 Companies such as InSitu Technologies (US), Intravascular Imaging Incorporated (i3) (US), Agile Devices (US), and Evident Vascular (US) are among the emerging players in the market, distinguished by focused technical expertise and specialized device capabilities. Top Strategic CAPEX Projects ➢ Medtronic (USA): Spending ~$1.2B to expand high-capacity production of transcatheter aortic valve replacement (#TAVR) systems, drug-eluting stents (DES), and structural heart delivery catheters. ➢ Boston Scientific (USA): Allocating ~$850M toward next-generation intravascular lithotripsy (#IVL), structural heart implants & advanced image-guided catheters. ➢ Terumo Corporation (Japan): Channeling ~$500M into scaling up production facilities for complex micro-catheters, specialized guidewires & radial access kits. #CardiologyDevices #DrugElutingStents #IVUS #OCT #CardiovascularDevices #MedicalDevices #StructuralHeart #MedTech #HealthcareInnovation #MinimallyInvasiveSurgery #HealthcareTechnology

4